Bettina Peuser

Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study—XELAVIRI (AIO KRK0110)

Dominik Paul Modest, Ludwig Fischer von Weikersthal, Thomas Decker et al. · Journal of Clinical Oncology · 2018 · 50 citations

Medicine, Oncology, Pharmacology +16

Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3

Laura Fischer, Sebastian Stintzing, Ludwig Fischer von Weikersthal et al. · British Journal of Cancer · 2022 · 17 citations · Full text

Medicine, Geriatric Medicine, Oncology +14

Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110)

Kathrin Heinrich, Dominik Paul Modest, Ingrid Ricard et al. · European Journal of Cancer · 2021 · 16 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110)

Myrto Boukovala, Dominik Paul Modest, Ingrid Ricard et al. · ESMO Open · 2024 · 10 citations · Full text

Medicine, Oncology, Pharmacology +17